Clinical Trial Update: Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial evaluating trastuzumab (Herceptin) plus paclitaxel (Taxol) for breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Taxol (paclitaxel)

Snippet

Sponsor: Harold J. Burstein, MD, PhD | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED